Overview

  • Product name

    Anti-2N Tau antibody [EPR21723]
    See all 2N Tau primary antibodies
  • Description

    Rabbit monoclonal [EPR21723] to 2N Tau
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WBmore details
    Unsuitable for: IHC-Fr or IHC-P
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human 2N Tau aa 50-150. The exact sequence is proprietary.
    Database link: P10636

  • Positive control

    • WB: His-tagged human 2N3R Tau recombinant protein (aa1-410); His-tagged human 2N4R Tau recombinant protein (aa1-441); Human and mouse hippocampus and brain lysates; Rat hippocampus lysate.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab218316 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 36-75 kDa (predicted molecular weight: 78 kDa).
  • Application notes
    Is unsuitable for IHC-Fr or IHC-P.
  • Target

    • Relevance

      Developmental stage: Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain. Disease: Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons. Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration. Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease. Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. Domain: The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats. Function: Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. PTM: Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis. Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur. Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD. Similarity: Contains 4 Tau/MAP repeats. Tissue specificity: Expressed in neurons. Expressed in the central nervous system.
    • Database links

    • Alternative names

      • 2N3R Tau antibody
      • 2N4R Tau antibody
      • Tau-C antibody

    Images

    • All lanes : Anti-2N Tau antibody [EPR21723] (ab218316) at 1/1000 dilution

      Lane 1 : Human hippocampus lysate
      Lane 2 : Human brain lysate
      Lane 3 : Human stomach lysate
      Lane 4 : Mouse hippocampus lysate
      Lane 5 : Mouse brain lysate
      Lane 6 : Mouse stomach lysate
      Lane 7 : Rat hippocampus lysate

      Lysates/proteins at 20 µg per lane.

      Secondary
      Lanes 1-3 : VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/1000 dilution
      Lanes 4-7 : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

      Predicted band size: 78 kDa
      Observed band size: 36-75 kDa
      why is the actual band size different from the predicted?



      Exposure time : Lanes 1-3: 3 minutes; Lanes 4-6: 59 seconds; Lane 7: 3 minutes.

      Blocking/Dilution buffer: 5% NFDM/TBST.

      This blot was developed using a higher sensitivity ECL substrate.

      Negative control: Mouse stomach, human stomach. PMID:8752131; PMID:11727254.

    • All lanes : Anti-2N Tau antibody [EPR21723] (ab218316) at 1/1000 dilution

      Lane 1 : His-tagged human 2N3R Tau recombinant protein (aa1-410), 10 ng
      Lane 2 : His-tagged human 2N4R Tau recombinant protein (aa1-441), 10 ng
      Lane 3 : His-tagged human 0N3R Tau recombinant protein (aa1-352), 10 ng
      Lane 4 : His-tagged human 0N4R Tau recombinant protein (aa1-383), 10 ng
      Lane 5 : His-tagged human 1N3R Tau recombinant protein (aa1-381), 10 ng
      Lane 6 : His-tagged human 1N4R Tau recombinant protein (aa1-412), 10 ng

      Secondary
      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

      Predicted band size: 78 kDa



      Exposure time : Lane 1: 1 second; Lanes 2-8: 3 seconds.

      Blocking/Dilution buffer: 5% NFDM/TBST.

      This antibody specifically recognizes 2N3R and 2N4R tau recombinant proteins. The lower bands maybe degraded tau fragments (PMID:28045602).

    References

    ab218316 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab218316.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up